A61K39/012

Compositions and methods of enhancing immune responses
11497801 · 2022-11-15 ·

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

Compositions and methods of enhancing immune responses
11497801 · 2022-11-15 ·

A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

Synthesis of diverse glycosylphosphatidylinositol glycans from Toxoplasma gondii and their application as vaccines and diagnostics

The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.

Synthesis of diverse glycosylphosphatidylinositol glycans from Toxoplasma gondii and their application as vaccines and diagnostics

The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.

YEAST VACCINE VECTOR INCLUDING IMMUNOSTIMULATORY AND ANTIGENIC POLYPEPTIDES AND METHODS OF USING THE SAME

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.

GENETICALLY MODIFIED COCCIDIAN PARASITES USEFUL AS VACCINES

A genetically modified coccidian parasites wherein expression of phosphatidylthreonine synthase (PTS) is disrupted, a polynucleotide including a nucleotide sequence encoding a phosphatidylthreonine synthase (PTS) enzyme, which catalyzes the production of a lipid, phosphatidylthreonine (PtdThr). PtdThr is an exclusive, major and physiologically important lipid in selected coccidian parasites, which is required for a normal growth and virulence of coccidian parasites. Coccidian parasites, having the expression of PTS disrupted as described herein, are useful as vaccines. The phosphatidylthreonine synthase enzyme and the nucleotide encoding sequences thereof as well as the phosphatidylthreonine phospholipid can find use in diagnostic methods and diagnostic kits or in vaccine and drug development applications.

GENETICALLY MODIFIED COCCIDIAN PARASITES USEFUL AS VACCINES

A genetically modified coccidian parasites wherein expression of phosphatidylthreonine synthase (PTS) is disrupted, a polynucleotide including a nucleotide sequence encoding a phosphatidylthreonine synthase (PTS) enzyme, which catalyzes the production of a lipid, phosphatidylthreonine (PtdThr). PtdThr is an exclusive, major and physiologically important lipid in selected coccidian parasites, which is required for a normal growth and virulence of coccidian parasites. Coccidian parasites, having the expression of PTS disrupted as described herein, are useful as vaccines. The phosphatidylthreonine synthase enzyme and the nucleotide encoding sequences thereof as well as the phosphatidylthreonine phospholipid can find use in diagnostic methods and diagnostic kits or in vaccine and drug development applications.

Compositions and Methods for Regulation of Chronic Toxoplasma Infection
20220235101 · 2022-07-28 ·

The present disclosure provides genetically altered protozoan parasites comprising a mutation in a bradyzoite formation deficient 1 (BFD1) gene, wherein the mutation inhibits differentiation of the parasite into a bradyzoite. The genetically altered protozoan parasites can be utilized in vaccine compositions and in methods of treating apicomplexan parasite infection.

USE OF BENZOIC ACID AND ESSENTIAL OIL COMPOUNDS FOR IMPROVING GROWTH PERFORMANCE
20220225638 · 2022-07-21 ·

This invention relates to a composition comprising benzoic acid, derivatives or metabolites thereof, optionally in combination with a mixture of at least one essential oil compounds selected from the group consisting of thymol, eugenol and piperine, for improving growth performance of an animal subjected to coccidiosis vaccine challenge, and use thereof.

USE OF BENZOIC ACID AND ESSENTIAL OIL COMPOUNDS FOR IMPROVING GROWTH PERFORMANCE
20220225638 · 2022-07-21 ·

This invention relates to a composition comprising benzoic acid, derivatives or metabolites thereof, optionally in combination with a mixture of at least one essential oil compounds selected from the group consisting of thymol, eugenol and piperine, for improving growth performance of an animal subjected to coccidiosis vaccine challenge, and use thereof.